Mayo Clinic signs dementia biomarker deal; Karolinska Institutet to lead $13.3M EU project;

> Mayo Medical Laboratories has signed a non-exclusive license with A&G Pharmaceutical for progranulin and plans to offer the first commercial blood test to predict progranulin mutation status in patients suspected to have frontotemporal dementia (FTD). Press release

> The Karolinska Institutet has been chosen to coordinate BIOMARKAPD, a SEK90 million ($13.3 million) EU project on neurodegenerative diseases, which will focus on biomarkers in Alzheimer's and Parkinson's diseases. Press release

 > Lab21 has launched a new Clinical Genomics Center as part of the Greenville Hospital System Institute for Translational Oncology Research (ITOR) to support the introduction of biomarker analysis into routine cancer patient management. Press release

> German small molecule drug discovery company Origenis is developing biomarkers to support the preclinical in-house development of its potential Parkinson's disease therapeutics targeted at LRRK2. Press release

> Diagnostics company Vermillion ($VRML) has been granted a U.S. patent for its platelet biomarkers for cancer. Press release

> Cystatin C can predict short- and long-term outcomes in primary percutaneous coronary intervention for patients with myocardial infarction. Abstract

> Progastrin predicts the chance of developing colorectal cancer in people with colon polyps. Abstract

> Exonhit has received an EU grant through the RESPONSIFY consortium to identify biomarkers that predict response to breast cancer therapy. Press release

> Indian genomics research and diagnostic testing company Xcelris Labs will distribute Epistem's biomarker-based tuberculosis assay once it is approved and launched. Article

> Changes in serum brain-derived neurotrophic factor (BDNF) levels may help in monitoring treatment response in bipolar disorder. Abstract

> pH has potential as a biomarker of early degeneration in Huntington's disease. Abstract

> In mouse lymphoma cells, moesin could act as a biomarker for carcinogens. Abstract

And Finally… Europe is investing in biomarkers in the U.K.'s West Midlands. Abstract